CGM for Non-Diabetics

TL;DR

CGM in non-diabetics shifts glucose monitoring from reactive disease management to proactive metabolic optimization. Standard lab ranges (fasting <100 mg/dL, HbA1c) mask dangerous subclinical glycemic variability — elite performers keep fasting glucose 72–85 mg/dL, post-meal peaks <110 mg/dL, and CV% <20%. Glucose spikes drive eNOS uncoupling, vascular oxidative stress, and HRV suppression. Key interventions: post-meal walking (10–15 min within 30 min of eating), vinegar pre-loads, protein-first meal sequencing.

Why it matters for Vitals

CGM data directly feeds the Vitals metabolic and recovery stack:

• HRV suppression: nocturnal glucose excursions trigger sympathetic stress → HRV drops + RHR elevates, masking true recovery
• Sleep disruption: late-day glucose spikes → nocturnal autonomic arousal → fragmented sleep
• Recovery scoring: glycemic variability is a confound for readiness metrics; athletes with high glycemic variability appear to recover worse even when training is equal
• Metabolic flexibility: CGM reveals insulin sensitivity in ways fasting glucose and HbA1c cannot — critical for body-composition interpretation
• Confounder detection: distinguishing genuine overtraining HRV dips from dietary glycemic stress

Key Facts

Parameter	Value
Devices	Dexcom G6/G7, Abbott FreeStyle Libre, Medtronic Guardian
Measurement	Interstitial fluid (ISF) glucose via glucose oxidase biosensor
Lag time	5–25 min during rapid flux (post-meal, exercise); minimal at steady state
Optimal fasting glucose	72–85 mg/dL
Optimal 24h mean	89–106 mg/dL (elite performers)
Optimal post-meal peak	<110 mg/dL; delta ~20 mg/dL above baseline
Optimal TIR	93–97% (time in 70–140 mg/dL range)
Optimal CV%	<20% (glycemic variability)
Clinical “normal” fasting	<100 mg/dL (insufficient — masks subclinical variability)

Key Metrics

Time in Range (TIR)

% of 24h where ISF glucose stays 70–140 mg/dL. Healthy non-diabetics typically >93%. Foundational homeostasis metric.

Glycemic Variability (CV%)

SD ÷ mean glucose × 100. Primary marker of glycemic stability and oxidative stress risk. CV% is arguably more deleterious to cardiovascular health than sustained stable hyperglycemia — rapid glucose shifts are the primary catalysts for endothelial oxidative stress. Optimal <20%.

Peak Amplitude (c_max)

Absolute maximum glucose after a metabolic stimulus (typically 45–60 min post-ingestion). High peaks drive vascular oxidative stress. Optimal <110–120 mg/dL.

Glucose Recovery Time to Baseline (GRTB)

Duration for ISF glucose to return to pre-stimulus baseline. Quantifies peripheral insulin sensitivity efficiency. Healthy metabolic system returns within 2–3 hours. Expanded GRTB + high c_max = early-warning indicator of declining metabolic flexibility.

Incremental AUC (iAUC)

AUC calculated exclusively above pre-meal baseline. More precise indicator of acute glycemic response — isolates stimulus from baseline.

Postprandial Glucose Physiology

Healthy spike: Moderate rise, peaks <110–120 mg/dL within 30–90 min, sharp efficient return to baseline. Indicates intact first-phase insulin response and excellent peripheral insulin sensitivity.

Sustained elevation: Glucose breaches 140 mg/dL, remains elevated >2–3 hours. Indicates blunted first-phase (failing to suppress hepatic output) + peripheral insulin resistance.

First-phase insulin response: Rapid immediate burst of pre-synthesized insulin within minutes of glycemic stimulus. Primary mandate: suppress hepatic glucose output — NOT peripheral disposal. A robust first-phase prevents endogenous glucose from overlapping with dietary glucose.

Endothelial Function Impact

Glucose spikes trigger eNOS uncoupling — the primary vascular damage pathway:

1. High glucose → upregulated eNOS + slightly increased NO
2. Massive ROS generation via NADPH oxidases (NOX2 activation)
3. O₂⁻ + NO → peroxynitrite (ONOO⁻) — highly cytotoxic
4. NO depletion → impaired vasodilation
5. BH₄ oxidation → eNOS uncoupling → enzyme generates MORE superoxide
6. Self-amplifying vicious cycle of vascular oxidative stress

Human evidence: Oral glucose tolerance testing (25g) induces significantly higher arterial stiffness (baPWV, CAVI) at 30, 60, 90 min. Whitehall II Study: post-challenge glucose peak amplitudes are stronger predictors of long-term arterial stiffening than fasting glucose or HbA1c. HbA1c mathematically erases the daily volatility driving eNOS uncoupling.

Wearable Integration

Glucose–HRV correlation

Synchronized ECG + CGM studies: elevated nocturnal ISF glucose shows moderate negative cross-correlation with HRV (average r = −0.453).

Mechanism: Glucose fluctuations/hyperglycemia → systemic sympathetic stress → catecholamine release → vagal suppression → HRV drops + RHR elevates.

Practical implication: A late-evening carbohydrate load inducing prolonged glucose excursion will systematically depress overnight HRV and elevate RHR, masking true recovery status.

Sleep–glucose bidirectional loop

Sleep deprivation → elevated cortisol + growth hormone → hepatic gluconeogenesis + peripheral insulin resistance. Fragmented sleep → next-day fasting glucose 12–18% higher in athletes + exaggerated post-meal spikes.

Normal vs Optimal Ranges

Parameter	Clinical “Normal”	CGM-Derived Optimal
Fasting Glucose	<100 mg/dL	72–85 mg/dL
24h Mean Glucose	Not standardized	89–106 mg/dL
Post-Meal Peak	<140 mg/dL	<110 mg/dL
TIR	>70% (ADA)	93–97%
Time Above 140 mg/dL	Not defined	<4%

J-curve: Individuals with fasting glucose 72–85 mg/dL have lowest all-cause mortality. Fasting glucose 91–99 mg/dL = 3× higher T2D risk vs <83 mg/dL — despite BOTH being “normal” by clinical standards.

Key Interventions

Post-meal walking

10–15 min within 30 min of meal completion — coincides with physiological glucose peak. Mechanism: skeletal muscle contraction → AMPK activation → GLUT4 translocation → insulin-independent glucose uptake. Delaying until 2h post-meal yields substantially weaker effects.

Vinegar pre-loads

1–2 tbsp vinegar in water prior to carbs. Mechanisms: (1) competitive alpha-amylase inhibitor → slows starch hydrolysis; (2) enhances skeletal muscle blood flow → increases peripheral glucose uptake. Meta-analyses: reduces postprandial glucose AUC by 0.60 SD → peak amplitude reductions ~20–30 mg/dL.

Protein/fat/fiber first meal sequencing

Fiber + fats + proteins before carbohydrates. Soluble fiber forms viscous gel barrier → retards glucose absorption. Protein pre-load (25g, 30 min prior) + fat → strongly stimulates GLP-1/GIP → slows gastric emptying → proactively augments first-phase insulin response. Evidence: reduces postprandial glucose excursions ~22% vs eating carbs first.

Sleep quality

High-quality sleep directly restores insulin sensitivity and stabilizes daytime glucose profiles. Fragmented sleep is both a cause and consequence of glycemic instability.

Wearable Detection Consideration

Vitals cannot directly measure glucose — but CGM data is a contextual input for interpreting HRV and sleep signals:

• High overnight glycemic variability → expect HRV suppression not attributable to training load
• Post-prandial glucose excursions → correlate with next-day readiness score depression
• Metabolic flexibility assessment requires simultaneous CGM + HRV + sleep data

AI integration (DTRE algorithms): Ingest continuous non-invasive wearable data (HR, HRV, sleep efficiency, circadian timing) → forecast blood glucose excursions 30–120 min in advance. Resting HR, insulin sensitivity baselines, and time-of-day are critical features.

Limitations and Artifacts

• ISF lag: 5–25 min during rapid flux — CGM underestimates blood glucose during rapid rise, overestimates during rapid drop
• Compression lows: nocturnal pressure on sensor → falsely low readings — verify with finger-stick before corrective action
• Dehydration: alters ISF volume → falsely elevated or depressed readings
• Algorithmic smoothing: devices use predictive filters adding further latency

Related

Glycemic Variability (mechanism note — consider creating if reused across notes)